<font color="red">Long_1</font> <font color="red">-_1</font> <font color="red">term_1</font> <font color="red">survival_1</font> in a phase III , randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma . 
<br>
<br> BACKGROUND We have continued to monitor the survival of patients randomised in a previously reported multicentre phase III study of topotecan versus paclitaxel in patients with advanced epithelial ovarian cancer who had failed one prior platinum - based regimen . 
<br> PATIENTS AND METHODS Patients with bidimensionally measurable disease were randomised to topotecan ( 1.5 mg / m(2)/day for 5 days ) or paclitaxel ( 175 mg / m(2)/day as a 3-h infusion ) every 21 days . Patients were eligible for treatment with the alternate therapy at third line . <font color="red">The_1</font> <font color="red">European_1</font> <font color="red">Organisation_1</font> <font color="red">for_1</font> <font color="red">Research_1</font> <font color="red">and_1</font> <font color="red">Treatment_1</font> <font color="red">of_1</font> <font color="red">Cancer_1</font> <font color="red">Quality_1</font> <font color="red">of_1</font> <font color="red">Life_1</font> <font color="red">(_1</font> <font color="red">EORTC_1</font> <font color="red">QOL)-C30_1</font> <font color="red">questionnaire_1</font> was also used to measure eight symptoms at baseline and during each course ( <font color="red">pain_1</font> <font color="red">,_1</font> <font color="red">anorexia_1</font> <font color="red">,_1</font> <font color="red">diarrhoea_1</font> <font color="red">,_1</font> <font color="red">fatigue_1</font> <font color="red">,_1</font> <font color="red">nausea_1</font> <font color="red">and_1</font> <font color="red">vomiting_1</font> <font color="red">,_1</font> <font color="red">dyspnea_1</font> <font color="red">,_1</font> <font color="red">constipation_1</font> <font color="red">and_1</font> <font color="red">insomnia_1</font> <font color="red">)_1</font> . 
<br> RESULTS A total of 226 patients were evaluable for response . Demographic characteristics were similar in both treatment groups , as were results of the EORTC QOL-30 questionnaire . For the topotecan group , <font color="red">median_1</font> <font color="red">time_1</font> <font color="red">to_1</font> <font color="red">progression_1</font> was 18.9 weeks ( range < 1 to 92.6 + weeks ; 25% censored ) , and , for paclitaxel , 14.7 weeks ( range < 1 to 137.3 + weeks ; 12.3% censored ) ; P = 0.076 . At 4 years post - randomisation , <font color="red">median_1</font> <font color="red">survival_1</font> in the topotecan group was 63.0 weeks ( range < 1 to 238.4 + weeks ; 20.5% censored ) and , for paclitaxel , 53.0 weeks ( range < 1 to 226.3 + weeks ; 12.3% censored ) ; P = 0.44 . 
<br> CONCLUSION Topotecan continues to demonstrate comparable <font color="red">efficacy_1</font> and <font color="red">survival_1</font> to paclitaxel with manageable and non - cumulative <font color="red">haematological_1</font> <font color="red">toxicity_1</font> <font color="red">._1</font> <font color="red">Non_1</font> <font color="red">-_1</font> <font color="red">haematological_1</font> <font color="red">toxicity_1</font> was generally mild for both groups . The <font color="red">long_1</font> <font color="red">-_1</font> <font color="red">term_1</font> <font color="red">survival_1</font> <font color="red">rate_1</font> indicates substantial therapeutic benefit for this group of patients receiving topotecan at relapse of ovarian cancer .